In answering "yes" to Questions 1, 2, and 3, the jury found that (i) AstraZeneca exercised market power within the relevant market, (ii) the settlement of the AstraZeneca-Ranbaxy patent litigation included a large and unjustified payment by AstraZeneca to Ranbaxy, and (iii) AstraZeneca's Nexium settlement with Ranbaxy was unreasonably anticompetitive (i.e., that the anticompetitive effects of that settlement outweighed any procompetitive justifications).. ..